RU2019115784A - Ингибиторы magl - Google Patents

Ингибиторы magl Download PDF

Info

Publication number
RU2019115784A
RU2019115784A RU2019115784A RU2019115784A RU2019115784A RU 2019115784 A RU2019115784 A RU 2019115784A RU 2019115784 A RU2019115784 A RU 2019115784A RU 2019115784 A RU2019115784 A RU 2019115784A RU 2019115784 A RU2019115784 A RU 2019115784A
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
acceptable salt
solvate
alkyl
paragraphs
Prior art date
Application number
RU2019115784A
Other languages
English (en)
Russian (ru)
Other versions
RU2019115784A3 (OSRAM
Inventor
Шерил А. Грайс
Дэниел Дж. Бузард
Майкл Б. Шагхафи
Original Assignee
Абайд Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62145825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2019115784(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Абайд Терапьютикс, Инк. filed Critical Абайд Терапьютикс, Инк.
Publication of RU2019115784A publication Critical patent/RU2019115784A/ru
Publication of RU2019115784A3 publication Critical patent/RU2019115784A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2019115784A 2016-11-16 2017-11-15 Ингибиторы magl RU2019115784A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423102P 2016-11-16 2016-11-16
US62/423,102 2016-11-16
PCT/US2017/061870 WO2018093949A1 (en) 2016-11-16 2017-11-15 Magl inhibitors

Publications (2)

Publication Number Publication Date
RU2019115784A true RU2019115784A (ru) 2020-12-17
RU2019115784A3 RU2019115784A3 (OSRAM) 2021-03-12

Family

ID=62145825

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019115784A RU2019115784A (ru) 2016-11-16 2017-11-15 Ингибиторы magl

Country Status (27)

Country Link
US (2) US11059822B2 (OSRAM)
EP (1) EP3541820B1 (OSRAM)
JP (1) JP7042468B2 (OSRAM)
KR (1) KR20190080935A (OSRAM)
CN (1) CN110267962B (OSRAM)
AU (1) AU2017361253B2 (OSRAM)
BR (1) BR112019009880A2 (OSRAM)
CA (1) CA3043617A1 (OSRAM)
CL (1) CL2019001336A1 (OSRAM)
CO (1) CO2019004945A2 (OSRAM)
CR (1) CR20190239A (OSRAM)
DO (1) DOP2019000118A (OSRAM)
EA (1) EA038150B1 (OSRAM)
EC (1) ECSP19034535A (OSRAM)
ES (1) ES2952582T3 (OSRAM)
IL (1) IL266547B (OSRAM)
JO (1) JOP20190107A1 (OSRAM)
MA (1) MA46855A (OSRAM)
MX (1) MX389627B (OSRAM)
NI (1) NI201900049A (OSRAM)
PE (1) PE20191145A1 (OSRAM)
PH (1) PH12019501079A1 (OSRAM)
RU (1) RU2019115784A (OSRAM)
TN (1) TN2019000149A1 (OSRAM)
UA (1) UA125523C2 (OSRAM)
WO (1) WO2018093949A1 (OSRAM)
ZA (1) ZA201903099B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197192A1 (en) * 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
MA58133B1 (fr) 2016-11-16 2024-02-29 H Lundbeck As Une forme cristalline d'un inhibiteur de magl
WO2018093950A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations
AU2018271876B2 (en) 2017-05-23 2021-10-21 H. Lundbeck A/S. Pyrazole MAGL inhibitors
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
PE20200664A1 (es) 2017-08-29 2020-06-11 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso
PE20200665A1 (es) 2017-08-29 2020-06-11 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso
CA3106510A1 (en) * 2018-07-19 2020-01-23 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
EP4474017A3 (en) 2018-08-13 2025-02-26 F. Hoffmann-La Roche AG New heterocyclic compounds
MX2022013224A (es) 2020-04-21 2022-11-14 H Lundbeck As Sintesis de un inhibidor de la monoacilglicerol lipasa.
UY39516A (es) 2020-11-13 2022-05-31 H Lundbeck As Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión
EP4457213A4 (en) 2021-12-29 2025-12-17 Psy Therapeutics Inc INHIBITION OF MONOACYLGLYCEROL LIPASE (MAGL)
WO2023213854A1 (en) 2022-05-04 2023-11-09 H. Lundbeck A/S Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor.
WO2024168426A1 (en) 2023-02-13 2024-08-22 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1003002A (en) 1910-10-10 1911-09-12 Gustave J Martel Tire-patching device.
WO2002070523A1 (en) 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
EP1948630A2 (en) 2005-11-05 2008-07-30 AstraZeneca AB Novel compounds
EP2065369A4 (en) 2006-08-23 2011-12-28 Astellas Pharma Inc UREA CONNECTION OR SALT THEREOF
JP2011513421A (ja) 2008-03-05 2011-04-28 ターガセプト，インコーポレイテッド サブタイプ選択的なジアザビシクロアルカンのアミド
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
US8575296B2 (en) 2009-09-29 2013-11-05 Polyone Corporation Polyester articles having simulated metallic or pearlescent appearance
ES2735411T3 (es) 2009-10-23 2019-12-18 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de orexina
AU2011223898A1 (en) 2010-03-04 2012-09-13 Merck Sharp & Dohme Corp. Positive allosteric modulators of mGluR2
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
JP2015508407A (ja) 2012-01-06 2015-03-19 アビデ セラピューティクス，インク． カルバメート化合物およびその製造および使用
JP2014005245A (ja) 2012-06-26 2014-01-16 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体を含有する医薬組成物
MA37940B1 (fr) 2012-09-25 2018-09-28 Hoffmann La Roche Derives d'octahydro-cyclopenta(c)pyrrole substitues inhibiteurs de l'autotaxine, utiles pour traiter les affections renales, hepatiques et inflammatoires, les affections du systeme nerveux, les maladies fibreuses.
WO2015003002A1 (en) 2013-07-03 2015-01-08 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
AP2016009496A0 (en) 2014-04-04 2016-10-31 X-Rx Inc Substituted spirocydic inhibitors of autotaxin
WO2015179559A2 (en) 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2016149401A2 (en) * 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
CN107849021A (zh) 2015-05-11 2018-03-27 阿比德治疗公司 治疗炎症或神经性疼痛的方法
CN107849017B (zh) 2015-07-31 2021-03-30 辉瑞公司 作为magl抑制剂的1,1,1-三氟-3-羟基丙-2-基氨基甲酸酯衍生物及1,1,1-三氟-4-羟基丁-2-基氨基甲酸酯衍生物
WO2017087858A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
EP3377060B1 (en) 2015-11-20 2020-08-19 Lundbeck La Jolla Research Center, Inc. Pyrazole derivatives, processes for their preparation and uses thereof
CN109715613B (zh) 2016-03-31 2021-07-30 武田药品工业株式会社 杂环化合物
WO2017197192A1 (en) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
WO2018093950A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
MA58133B1 (fr) 2016-11-16 2024-02-29 H Lundbeck As Une forme cristalline d'un inhibiteur de magl
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
PL3595665T3 (pl) 2017-03-13 2025-01-13 Lundbeck La Jolla Research Center, Inc. Podwójne inhibitory magl i faah
AU2018271876B2 (en) 2017-05-23 2021-10-21 H. Lundbeck A/S. Pyrazole MAGL inhibitors
JOP20190267A1 (ar) 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
PE20200664A1 (es) 2017-08-29 2020-06-11 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso
PE20200665A1 (es) 2017-08-29 2020-06-11 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso
UY39516A (es) 2020-11-13 2022-05-31 H Lundbeck As Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión

Also Published As

Publication number Publication date
US11059822B2 (en) 2021-07-13
US20220135563A1 (en) 2022-05-05
US20200291023A1 (en) 2020-09-17
ZA201903099B (en) 2021-01-27
PE20191145A1 (es) 2019-09-02
MX389627B (es) 2025-03-20
EA038150B1 (ru) 2021-07-14
UA125523C2 (uk) 2022-04-13
CO2019004945A2 (es) 2019-05-21
CN110267962A (zh) 2019-09-20
MX2019005773A (es) 2019-12-05
TN2019000149A1 (en) 2020-10-05
JP2020500178A (ja) 2020-01-09
JOP20190107A1 (ar) 2019-05-09
DOP2019000118A (es) 2019-09-30
EP3541820A4 (en) 2020-06-10
IL266547B (en) 2022-06-01
ES2952582T3 (es) 2023-11-02
EP3541820B1 (en) 2023-07-05
NI201900049A (es) 2019-10-30
EP3541820C0 (en) 2023-07-05
EP3541820A1 (en) 2019-09-25
CA3043617A1 (en) 2018-05-24
RU2019115784A3 (OSRAM) 2021-03-12
AU2017361253B2 (en) 2021-08-05
MA46855A (fr) 2021-05-19
US11691975B2 (en) 2023-07-04
NZ753471A (en) 2021-01-29
BR112019009880A2 (pt) 2019-08-13
AU2017361253A1 (en) 2019-05-30
CN110267962B (zh) 2022-04-01
IL266547A (en) 2019-07-31
CR20190239A (es) 2019-06-26
JP7042468B2 (ja) 2022-03-28
ECSP19034535A (es) 2019-05-31
EA201991029A1 (ru) 2019-12-30
CL2019001336A1 (es) 2019-10-04
WO2018093949A1 (en) 2018-05-24
PH12019501079A1 (en) 2019-08-19
KR20190080935A (ko) 2019-07-08

Similar Documents

Publication Publication Date Title
RU2019115784A (ru) Ингибиторы magl
RU2019116514A (ru) Ингибиторы magl
RU2019116512A (ru) Ингибиторы magl
RU2016118768A (ru) Композиции, пригодные для лечения расстройств, связанных с kit
JP2020500178A5 (OSRAM)
JP2018504437A5 (OSRAM)
RU2020107039A (ru) Спироциклические соединения и способы их получения и применения
RU2014149149A (ru) БИЦИКЛИЧЕСКИЕ СУЛЬФОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORгамма АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
JP2017508789A5 (OSRAM)
JP2019034943A5 (OSRAM)
RU2016150486A (ru) Ингибиторы бета-лактамазы
JP2014015465A5 (OSRAM)
JP2020532545A5 (OSRAM)
JP2011530500A5 (OSRAM)
RU2016151727A (ru) Нейроактивные стероиды, композиции и их применения
JP2018529650A5 (OSRAM)
RU2020131276A (ru) Терапевтические соединения и композиции
RU2016108987A (ru) Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
RU2018119173A (ru) Производное бензофурана, способ его получения и его применение в медицине
JP2019531279A5 (OSRAM)
JP2017511815A5 (OSRAM)
JP2015517495A5 (OSRAM)
JP2020521767A5 (OSRAM)
RU2021100040A (ru) Конденсированные бициклические соединения для лечения заболевания
HRP20241540T1 (hr) Pirolotriazinski spojevi koji djeluju kao inhibitor mnk